左氧氟沙星辅助治疗耐多药肺结核临床效果及药学分析

Clinical Effect and Pharmacological Analysis of Levofloxacin Adjuvant Therapy for Multidrug-Resistant Pulmonary Tuberculosis

目的研究观察左氧氟沙星辅助治疗耐多药肺结核的临床效果并进行药学分析。方法随机抽取该院2016年2月—2017年8月期间收治的耐多药肺结核患者140例,根据就诊顺序的奇偶分为观察组和对照组,每组70例。对照组采用抗结核药物治疗,观察组在对照组的基础上增加左氧氟沙星辅助治疗,对比两组患者的治疗效果和不良反应。结果两组治疗第3、6、12、18个月时痰菌阴转情况对比差异有统计学意义(χ~2=4.050 9、4.480 0、4.238 9、6.496 2,P=0.044 1、0.034 2、0.039 5、0.010 8),观察组优于对照组;两组病灶吸收改善情况对比差异有统计学意义(χ~2=3.876 9,P=0.048 9),观察组优于对照组;观察组治疗总有效率高于对照组,差异有统计学意义(χ~2=4.772 7,P=0.028 9);不良反应率对比差异无统计学意义(χ~2=1.942 8,P=0.163 3),均无严重不良反应出现。结论采用左氧氟沙星辅助治疗的方法治疗耐多药肺结核的临床疗效显著,可以有效降低不良反应率,提高治疗效率,是一种高效、安全的治疗方法。

Objective To investigate the clinical effect of levofloxacin in the treatment of muhidrug-resistant tuberculosis and its pharmacological analysis. Methods A total of 140 patients with muhidrug-resistant pulmonary tuberculosis admitted to the hospital from February 2016 to August 2017 were randomly selected. The odds were divided into observation group and control group, 70 cases in each group. The control group was treated with anti-tuberculosis drugs. The observation group was given levofloxacin adjuvant therapy on the basis of the control group, and the treatment effect and adverse reac- tions of the two groups were compared. Results There were statistically significant differences in the negative conversion of sputum between the two groups at the 3rd, 6th, 12th and 18th months （χ^2=4.050 9, 4.480 0, 4.238 9, 6.496 2, P=0.044 1, 0.034 2, 0.039 5, 0.010 8）. The observation group was superior to the control group. There was a statistically significant difference in the improvement of lesion absorption between the two groups （χ^2=3.876 9, P=0.048 9）. The observation group was superior to the control group; the total effective rate of the observation group was higher than that of the control group, and the difference was statistically significant （χ^2=4.772 7, P=0.028 9）; there was no statistically significant difference in adverse reaction rate （χ^2=1.942 8, P=0.163 3）, and no serious adverse reactions occurred. Conclusion The clinical efficacy of lev-ofloxacin adjuvant therapy in the treatment of multidrug-resistant tuberculosis is significant, which can effectively reduce the adverse reaction rate and improve the treatment efficiency. It is an effective and safe treatment.